Company Overview and News

36
Market Live: Sensex extends losses amid trade war woes; IOC, HPCL, BPCL dip 3%

2018-06-19 moneycontrol
Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental abbreviated new drug application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina.
LIBERTSHOE 523768 500325 GUJBOROS RELIANCE KAJARIACER 532418 BHRQY GLKQY 532215 JUSTDIAL CMQMY 500470 535648 533407 AXISBANK RIGD 500233 CUMMINSIND BHARTIARTL 500790 NSZTY RLNIY SBAZ GLENMARK AXB 502219 IBN NESTLEIND HEXAWARE 539302 532129 AXBKY POWERMECH 532454 BOROSIL AXBA 500480 ICICIBANK TTST 532296 TATASTEEL TATLY 532174 CNOVAPETRO 526596 JSTQY ANDHRABANK

0
Kajaria Ceramics Limited - Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Top 12 stocks to invest ahead of May FO expiry which could give up to 6-20% return

2018-05-28 moneycontrol
The Nifty50 closed flat with a positive bias for the week ended May 25 above its crucial resistance level of 10,600. It was indeed a roller coaster rise for Nifty which rebounded nearly 200 points after hitting a low of 10,417 to close the week at 10,605 on Friday.
JUSTDIAL 532432 500408 532497 535648 KAJARIACER UNITDSPR UQNTY RADICO 500233 TATAELXSI JSTQY

0
Most FMCG firms beat Street math in Q4

2018-05-16 thehindubusinessline
Priya Kansara The consumer sector is among the few in the economy on which analysts and investors have pinned high hopes for a strong financial performance in the March quarter. And not without reason, given the low base of the post-demonetisation period and better macro environment compared to other industries.
500820 KAJARIACER DABUR NESTLEIND HINDUNILVR 533155 ASIANPAINT DBRQY JUBLFOOD 532424 GDRJY 500096 ZEEEY JBLWY 505537 500233 500696 GODREJCP ZEEL 500790 NSZTY

0
Kajaria Ceramics Limited - Reappointment

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Kajaria Ceramics Limited - Declaration for audit reports with unmodified opinion(s)

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Kajaria Ceramics Limited - Press Release

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Kajaria Ceramics Limited - Outcome of Board Meeting

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Kajaria Ceramics Limited - Financial Result Updates

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

0
Kajaria Ceramics Limited - Dividend

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

1
ABB, Mahindra Holidays results on Tuesday

2018-05-07 thehindubusinessline
Over two dozen companies including ABB India, AB Capital, Automotive Axles, Blue Dart Express, De Nora, Godrej Consumer, GTL Infra, HEG, Hindustan Composites, India Nippon, Jubilant Foodworks, Kajaria Ceramics, Huhtamaki PPL, Mahindra Holidays, Phoenix Mills, SKF India, Sun Pharma Advanced, Sadbhav Infrastructure, Sanofi India, Sintex Industries, Whirlpool of India and Vesuvius will declare their fourth quarter and annual results for the period ended March 2018 on Tuesday.
SANOFI ABB PHOENIXLTD KAJARIACER 533155 JUBLFOOD 509635 505010 PAPERPROD AUTOAXLES SINTEX 500002 JBLWY SKFINDIA 502742 500233 500674 ABBDY HINDCOMPOS 503100 500472 526612 BLUEDART 509820

0
Kajaria Ceramics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KAJARIACER 500233

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...